Has Douglas Wolf, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,421,095 in general payments to Douglas Wolf, MD across 2,447 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Douglas Wolf, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Douglas Wolf, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Douglas Wolf, MD

Gastroenterology · Atlanta, GANPI 1588649693

Payments from drug & device makers

$6,421,095in general payments, 2019–2025

Across 2,447 payments — averaging $2624.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Janssen Research & Development, LLC$1.7M
Bristol Myers Squibb$1.5M
AbbVie$1.2M
Takeda Pharmaceuticals U.S.A., Inc.$858K
Pfizer$602K
E.r. Squibb & Sons, L.L.C.$257K
plus $345K from 37 others

$44,513in research payments, 2019–2025

Across 13 payments — averaging $3424.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$29K
Pfizer$9K
UCB, Inc.$5K
Bristol Myers Squibb$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Janssen Research & Development, LLC	274	$1,662,162
Bristol Myers Squibb	100	$1,505,980
AbbVie(2 entities)	446	$1,190,761
Takeda Pharmaceuticals U.S.A., Inc.	849	$858,454
Pfizer(2 entities)	257	$601,690
E.r. Squibb & Sons, L.L.C.	56	$256,737
Johnson & Johnson	147	$157,312
Janssen Scientific Affairs, LLC	44	$64,483
UCB Biosciences Inc.	3	$49,090
Genentech, Inc.	32	$31,698
Eli Lilly	41	$26,408
UCB, Inc.	9	$8,351
Gilead	6	$2,694
Lilly USA, LLC	11	$2,025
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	57	$904
Merck	15	$359
Ipsen Biopharmaceuticals, Inc	10	$225
Intercept Pharmaceuticals, Inc.	13	$219
Celltrion USA Inc.	9	$186
Madrigal Pharmaceuticals	6	$164
Vivus LLC	7	$135
Regeneron Healthcare Solutions, Inc.	4	$109
Nestle Healthcare Nutrition Inc.	6	$109
Ironwood Pharmaceuticals, Inc	7	$108
Sandoz	4	$89
Phathom Pharmaceuticals, Inc.	4	$70
Sanofi	3	$66
Aimmune Therapeutics, Inc.	3	$61
Ferring Pharmaceuticals Inc.	4	$58
Convatec Inc.	1	$54
Novo Nordisk	2	$47
Ardelyx, Inc.	2	$41
AMAG Pharmaceuticals, Inc.	3	$41
Medtronic	1	$32
Daiichi Sankyo Inc.	2	$29
Amgen	1	$26
Redhill Biopharma Inc.	2	$24
Boehringer Ingelheim	1	$23
Mallinckrodt Hospital Products Inc.	1	$17
Exact Sciences	1	$16
Organon	1	$14
Alfasigma USA, Inc.	1	$13
Intra-sana Laboratories	1	$12

How this compares

$6,421,095 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia →

Medicare billing

Part B allowed, 2024

$95,428

Medicare patients

111

Services billed

2,150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Atlanta

Michael GalambosAtlanta$1.8M
Nitin GuptaAtlanta$1.7M
Heba IskandarAtlanta$978K
Cynthia RudertAtlanta$720K
Kavita KongaraAtlanta$492K
Girish AnandAtlanta$425K
Julia LiuAtlanta$412K
Norman GitlinAtlanta$399K
Saul KarpenAtlanta$368K
Roshan ShresthaAtlanta$323K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →